Iqirvo

Elafibranor, the active ingredient in Iqirvo, is a PPAR α/δ agonist presented as a 120 mg tablet for oral use. It treats non‑alcoholic steatohepatitis (NASH) in adult patients, particularly those with biopsy‑proven disease and fibrosis stage 2‑3. The drug works by modulating lipid metabolism, inflammation and fibrotic pathways in the liver.

GNH USA supplies Iqirvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows GMP standards and provides regulatory‑approved batches to healthcare providers across multiple regions.

Iqirvo (elafibranor) is a PPAR α/δ agonist used in the management of non‑alcoholic steatohepatitis (NASH).

- Non‑alcoholic steatohepatitis (NASH): reduces liver inflammation and fibrosis. - Biopsy‑proven NASH with fibrosis stage 2‑3: aims to improve liver histology. - Metabolic dysfunction‑associated NASH: targets abnormal lipid metabolism and inflammatory pathways.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools occurring intermittently. - Headache: transient cranial discomfort. - Fatigue: feeling of reduced energy.

Serious or Rare Side Effects: - Elevated liver enzymes: significant increase in ALT/AST levels. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Pancreatitis: abdominal pain with elevated pancreatic enzymes. - Hepatic decompensation: worsening liver function in advanced disease. - Cardiovascular events: rare occurrences of myocardial infarction or arrhythmia.

Before initiating therapy, clinicians should assess baseline liver function and monitor periodically during treatment.

- Monitor liver enzymes: check ALT/AST at baseline and regularly. - Assess cardiovascular risk: evaluate history of heart disease. - Evaluate renal function: adjust use if severe impairment is present. - Avoid in severe hepatic impairment: contraindicated in patients with Child‑Pugh C. - Pregnancy and breastfeeding: safety not established; avoid unless benefit outweighs risk. - Store below 25°C: keep in the original pack, protect from moisture.

Elafibranor may interact with several drug classes; careful review of concomitant medications is advised.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase elafibranor exposure. - Strong CYP3A4 inducers: may reduce therapeutic effect. - Bile acid sequestrants: can decrease absorption of elafibranor. - Other PPAR agonists: additive pharmacologic activity may increase adverse events.

Moderate Interactions (Monitor Closely): - Statins: monitor for increased risk of myopathy. - Anticoagulants (e.g., warfarin): observe for changes in INR. - Antidiabetic agents (e.g., metformin): watch for hypoglycemia when combined with other glucose‑lowering drugs.